Objectives. To assess the treatment effect of NSAIDs and TNF blockers in AS according to different domains of interest.
Introduction
The SpAs are a group of chronic inflammatory rheumatic disorders that present distinctive pathophysiological, clinical, radiographic and genetic features. AS is the most frequent subtype of SpA and can be considered as the prototype of this group [1] .
Therapeutic options for patients with AS have been limited during the past decades and the symptom-modifying anti-rheumatic drugs, especially the NSAIDs, have been the cornerstone of pharmacological intervention. Indeed, several studies suggested that NSAIDs reduce signs and symptoms in patients with AS and, in the case of low back pain, a good response to NSAIDs has even been identified as a suggested sign for the diagnostic of SpAs [2] . However, the effect of these drugs on disease progression is uncertain. The introduction of TNF-a blockers marked a turning point in the management of AS [3] . From the beginning, the NSAIDs and TNF blockers have been viewed as independently by the rheumatologists because of their specific different mode of action. Moreover, the use of these drugs in daily practice is also completely different since TNF blockers are only used in NSAID-refractory patients and on top of NSAIDs. Because of their mechanism of action, NSAIDs are usually considered as 'symptomatic' drugs, whereas TNF blockers as 'disease-modifying' drugs. By analogy with RA, the definition of 'disease-modifying effect' is usually reserved for the drugs able to reduce the structural progression of the disease. In AS, the observable data concerning this structural effect are more confusing since the single trial suggesting a structural effect evaluated NSAIDs [4] . At variance, all the trials evaluating TNF blockers failed to demonstrate a structural effect.
Different health domains [5] [6] [7] [8] [9] , such as pain, function or inflammation, can be used to assess the response to anti-rheumatic drugs in AS. The effects of NSAIDs and TNF blockers could differ according to one or more domains and some specific domains could better differentiate these two therapies.
These preliminary remarks prompted us to assess the treatment effect of NSAIDs and TNF blockers in AS according to different domains of interest. A meta-analysis of published randomized controlled trials (RCTs) reporting the effects of NSAIDs/TNF-a blockers in AS was then performed.
Methods

Literature research
Two electronic searches were performed by one investigator using Medline 
Study selection
Study inclusion criteria were as follows: use of the modified New York criteria [10] to define AS; RCT design with a control group receiving placebo and an active group receiving any NSAIDs or TNF blockers; assessment of the response to treatment according to at least one of the following domains: pain, disease activity, physical function, patient's global assessment, spinal mobility, morning stiffness, fatigue or acute-phase reactants; and results permitting evaluation of effect size.
Methodological quality
The Jadad score [11] was applied to assess methodological quality of RCTs and used to classify quality as high (Score 5), moderate (Score 4) or low (Scores 1-3).
Data extraction
Data extraction was performed by one reviewer (C.E.) using a predefined data extraction form. Information extracted included: first author, publication year, Jadad score, number of patients in active and control group, type of NSAIDs or TNF blockers and dose, mean age/ sex ratio/percentage of patients with positive HLA-B27/ disease duration of participants, date of endpoint, outcome measure and mean change/S.D. for each outcome measure.
The 
Statistical analysis
To determine the magnitude of the treatment effect, an effect size was calculated by the standardized mean difference (SMD) [12] , which is the difference of the means divided by the pooled S.D. By convention (Cohen categories), an effect size between 0.2 and 0.5; between 0.5 and 0.8 and >0.8 is usually considered as small, medium or large, respectively. To include studies with multiple intervention groups, all relevant experimental intervention groups of the study were combined into a single group in order to create a single pair-wise comparison, as recommended by the Cochrane Handbook for systematic reviews of interventions.
Statistical heterogeneity was tested by Q-test to calculate an I 2 -value [13, 14] . Data were meta-analysed using fixed effects models if the I 2 -value was <50% and using random effects models in the case of important heterogeneity (I 2 ! 50%). Sensitivity analysis was conducted to determine whether exclusion of studies of low quality influenced the results. Meta-analyses were conducted using RevMan analyses software (RevMan 4.2.10; Cochrane Collaboration, Oxford, UK).
Results
Study selection
The results of the article selection process for TNF blockers and the NSAID group are reported in Fig. 1 . For the TNF blocker group, 240 citations were identified by key words and hand search, and 215 were excluded after abstract lecture. From the 25 remaining articles, 11 were excluded for duplicate, 1 because patients were suffering from PsA and not AS, and 5 for missing data to calculate an effect size. Consequently, eight articles [15] [16] [17] [18] [19] [20] [21] [22] met our inclusion criteria and were included in the meta-analysis. For the NSAID group, 135 articles were selected by key words and hand search and 15 were selected on the basis of abstract. From the 15 remaining articles, 2 were excluded for lack of a placebo group and 8 for missing data to calculate an effect size. Consequently, five articles [23] [24] [25] [26] [27] were selected and included in the meta-analysis.
Characteristics of included studies
Characteristics of the TNF blocker and NSAID studies are presented in Tables 1 and 2 . Infliximab was investigated in three studies, etanercept in four and adalimumab (ADA) in one. Four studies had multiple treatment groups: Van The average time to endpoint was 10.1 weeks (range 2-24 weeks): 14.5 weeks (range 6-24 weeks) and 5.6 weeks (range 2-8 weeks) for the TNF blocker studies and the NSAID studies, respectively. Eight studies reported data to calculate an effect size for the domain 'pain', 10 for the domain 'function' and 6 for the domain 'acute-phase reactants'. No study reported the outcome 'fatigue' and no NSAID study reported data to calculate an effect size for the outcome 'activity'.
The mean Jadad score was 4.4 (range 3-5) for the TNF blocker studies and 3.8 (range 1-5) for the NSAID studies. Two studies [15, 26] differed from the others by a low methodological quality.
This systematic review included 2487 AS patients, 1407 in the TNF blocker RCTs and 1080 in the NSAID RCTs. The mean age of the patients was 41.3 years (range 32-51 years), the mean disease duration was 10.7 years (range 7.7-16.4 years). There were 75% of men and 85% of the patients HLA-B27 positive. The mean BASFI Scores were 56 (range 32-67) for the TNF blocker studies and 49 (39-57) for the NSAID studies.
Meta-analyses
The effect sizes for TNF blockers/NSAIDs are detailed in Figs 2-4. There was significant heterogeneity between the TNF blocker/NSAID studies for several outcome measures (global assessment and mobility for the TNF blocker studies and pain, global assessment and morning stiffness for the NSAID studies). Concerning the domains function and acute-phase reactants, I
2 was systematically
<50%.
For the domains pain and patient's global assessment, the treatment effect was large for both TNF blockers and NSAIDs [for TNF blockers and NSAIDs, respectively: SMD (95% CI) À0. (10) 15 (10) 45 (21) Function, BASFI Placebo 20 39 (10) 12 (9) 32 ( . After excluding the study with low methodological quality [15, 26] , the results were comparable (data not shown). The results of pooled effect sizes for TNF blocker/NSAID studies are presented in Table 3 .
Discussion
This meta-analysis suggested that efficacy of NSAIDs and TNF blockers on patient-reported outcomes was broadly comparable and could be greater for TNF blockers in some outcomes such as patient's global assessment or function. TNF blockers and NSAIDs seemed to have no significant effect on mobility. The only significant difference in efficacy between the two therapies was observed for the domain acute-phase reactants: acute-phase reactants seemed to be uniquely reduced by TNF blockers. It appeared to be difficult to compare NSAID and TNF blocker studies. The methodological quality of the NSAID RCTs was worse than the TNF blocker RCTs. Moreover, NSAID studies had previous dates of publication. The outcome measures were collected later in the TNF blocker studies compared with the NSAID studies. For both NSAID and anti-TNF trials, the average time to endpoint matched with the efficient drug level. Indeed, for the TNF blockers, the improvement usually starts within 2 weeks of therapy, whereas a few days is enough to observe an NSAID effect. Nevertheless, the difference in the average time to endpoint between NSAID and TNF blocker trials may overrate or underestimate the efficacy of one therapy [20] Heterogeneity: χ 2 = 0.02, df = 1 (P = 0.88); l 2 = 0% Test for overall effect: Z = 10.16 (P < 0.00001) Heterogeneity: τ 2 = 0.27; χ 2 = 44.61, df = 4 (P < 0.00001); l 2 = 91% Test for overall effect: Z = 4.33 (P < 0.0001) compared with the other, depending on the natural progression of disease. The severity of patient disease, evaluated with the BASFI, was overall comparable in the two groups but reported in only two NSAID studies. Patients included in the NSAID trials did not receive any treatment or even were already known NSAID responders. Indeed, some NSAID studies used a so-called 'flare design', which means that patients already use NSAIDs before inclusion, they have to stop treatment and only if there is a certain increase in symptoms will they be included in the study. Thus, patients included in these studies were already known NSAID responders. In contrast, patients included in the TNF blocker studies usually already received NSAIDs, had high disease activity despite the use of these NSAIDs and TNF blockers were given on top of NSAIDs. Some other limitations in our study should be noted. First, the limited number of included studies. Eight TNF blocker RCTs were finally included, which is consistent given the fact that the publication of a small number of key studies had been sufficient to demonstrate the efficacy of each anti-TNF agent. For the NSAID group, only five studies were included. This low number could be explained by the exclusion of many studies for lack of control group or data not suitable for meta-analysis. Secondly, most of the studies did not report the results of all outcomes selected, each outcome measure was assessed in a variable number of studies and in different studies that could make difficult comparison between different domains. The outcome of acute-phase reactants was only reported in two NSAID studies, which could be explained by the fact that efficacy of NSAIDs on acute-phase reactants was rarely found in RCTS, and therefore rarely reported. Thirdly, there are limitations of some methods used in this study, such as using I 2 to assess heterogeneity [14] or including multiple intervention groups from one study, which could introduce some bias. Finally, there were no data to assess the effect of TNF blockers/NSAIDs on fatigue despite the fact that fatigue is an important source of morbidity in AS [28] . Despite this list of limitations, this reported study has several strengths and in particular the systematic analysis of all the potential trials and, at the end, the large number of evaluated patients. Taking into account these preliminary remarks, our study does confirm the clinically relevant symptomatic effect of both NSAIDs (in treatment naïve patients) and TNF blockers (in NSAIDs insufficiently controlled patients). Our study suggests that biological inflammation (e.g. acute-phase reactants) is the single domain differentiating NSAIDs and TNF blockers. Increased CRP Fig. 4 Efficacy of TNF blockers/NSAIDs in AS for the outcome 'Acute-phase reactants'. ETN: etanercept; IFX: infliximab. [29] . Despite the fact that TNF blockers have failed until now to demonstrate a structural effect in AS, such findings might be of clinical relevance and, at least, are a strong argument to clearly consider the TNF blockers not only as symptomatic treatment but potentially as disease-modifying drugs. Other studies are required to evaluate such disease-modifying effects, such as the capacity to prevent long-term disability and/or to prevent requirement for surgery such as in RA [30, 31] .
Rheumatology key message
. Acute-phase reactants are the domains that best distinguish TNF blockers and NSAIDs.
